BMAL1 and central nervous system cancer: Trends of increased survival and high-grade toxicity associated with morning TMZ administration suggest consistency with the pre-clinical findings of increased glioma cell cytotoxicity at the peak of bmal1 expression and the nadir of MGMT expression—both of which seemed to demonstrate important circadian rhythms.